

Comparison of metabolic syndrome prevalence using four different definitions – a population-based study in Finland

Haverinen E., Paalanen L., Palmieri L., Padron-Monedero A., Noguera-Zambrano I., Sarmiento Suárez R. & Tolonen H.

Additional file 3.

Prevalence of NCEP-ATP III metabolic syndrome components for total population, by gender and age groups

Total population and 95% CI identified with NCEP-ATP III obesity component (waist circumference (WC) M: 102 cm, f: 88 cm) (%)	Age groups	NCEP-ATP III WC component, men (%)	95% CI	NCEP-ATP III WC component, women (%)	95% CI
44.3 (43.0-45.6)	Total	37.7	35.9-39.6	50.0	48.2-51.8
	25-34	16.1	12.7-20.2	22.1	18.5-26.2
	35-44	24.9	21.0-29.2	38.3	34.1-42.7
	45-54	38.4	34.1-42.8	48.2	44.0-52.4
	55-64	49.0	45.0-53.0	57.7	53.8-61.5
	65-74	50.1	45.8-54.4	63.6	59.7-67.3
	75-	37.3	31.4-43.6	66.1	61.1-70.7
Total population and 95% CI identified with NCEP-ATP III triglyceride component (TG ≥ 150 mg/dl (1.7 mmol/L) (%)	Age groups	NCEP-ATP III triglyceride component, men (%)	95% CI	NCEP-ATP III triglyceride component, women (%)	95% CI
22.9 (21.8-24.0)	Total	28.8	27.1-30.6	17.8	16.5-19.2
	25-34	18.0	14.4-22.2	6.5	4.5-9.2
	35-44	27.3	23.3-31.7	9.3	7.0-12.2
	45-54	42.0	37.6-46.5	17.8	14.8-21.2
	55-64	31.5	27.9-35.3	23.7	20.5-27.2
	65-74	27.2	23.5-31.2	22.9	19.7-26.4
	75-	18.6	14.2-24.1	24.4	20.3-29.0
Total population and 95% CI identified with NCEP-ATP III HDL-C component M: HDL-C < 40 mg/dl (1.03 mmol/l) F: HDL-C < 50 mg/dl (1.3 mmol/l) (%)	Age groups	NCEP-ATP III HDL-C component, men (%)	95% CI	NCEP-ATP III HDL-C component, women (%)	95% CI
17.8 (16.8-18.8)	Total	15.5	14.2-16.9	19.8	18.4-21.2
	25-34	15.5	12.2-19.5	16.4	13.2-20.2
	35-44	16.4	13.2-20.2	22.5	19.0-26.4
	45-54	16.2	13.2-19.8	19.8	16.7-23.3
	55-64	14.9	12.3-18.0	17.2	14.4-20.4
	65-74	16.4	13.5-19.8	18.8	15.9-22.1
	75-	12.3	8.7-17.1	26.3	22.1-31.0
Total population and 95% CI identified with NCEP-ATP III blood pressure (BP) component (≥130/85) (%)	Age groups	NCEP-ATP III BP component, men (%)	95% CI	NCEP-ATP III BP component, women (%)	95% CI
60.0 (58.7-61.3)	Total	66.0	64.2-67.8	54.9	53.1-56.7
	25-34	44.8	39.8-49.9	17.1	13.9-20.9
	35-44	53.9	49.1-58.6	28.4	24.6-32.5
	45-54	65.5	61.1-69.6	54.2	50.0-58.3
	55-64	74.0	70.3-77.4	64.0	60.1-67.7
	65-74	80.0	76.3-83.2	77.9	74.4-81.0
	75-	70.8	64.7-76.2	82.7	78.5-86.2

Total population and 95% CI identified with NCEP-ATP III glucose component (FPG >100 mg/dl (5.6 mmol/l) or medication) (%)	Age groups	NCEP-ATP III glucose component, men (%)	95% CI	NCEP-ATP III glucose component, women (%)	95% CI
50.4 (49.1-51.7)	Total	60.1	58.2-62.0	42.1	40.4-43.9
	25-34	40.2	35.3-45.3	11.8	9.1-15.2
	35-44	47.3	42.6-52.1	19.9	16.6-23.7
	45-54	59.2	54.7-63.5	38.3	34.3-42.4
	55-64	65.9	62.9-69.6	47.5	43.6-51.4
	65-74	73.2	69.2-76.8	63.4	59.5-67.1
	75-	72.0	66.0-77.3	69.4	64.5-73.9

NCEP-ATP III= National Cholesterol Education Program Adult Treatment Panel III, WC= waist circumference, HDL-C= high density lipoprotein cholesterol, TGs= triglycerides, BP= blood pressure, T2DM= type 2 diabetes mellitus, FPG= fasting plasma glucose